OAKLAND, Calif., Sept. 24, 2026 /PRNewswire/ -- PG&E Corporation (NYSE: PCG) will hold a conference call on Thursday, October 22, 2026, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) to discuss its third quarter 2026 results. The public can access the conference call through a simultaneous webcast. The link is provided below and will also be available from the PG&E Corporation website.

A replay of the live conference call and webcast will be available at http://investor.pgecorp.com/news-events/events-and-presentations/default.aspx.

Alternatively, a toll-free replay of the conference call may be accessed shortly after the live call through October 29, 2026 by dialing (800) 770-2030. Confirmation code 92587 will be required to access the replay.

Please contact Investor Relations at [email protected] if you have any questions.

PG&E Corporation (NYSE: PCG) is a holding company headquartered in Oakland. It is the parent company of Pacific Gas and Electric Company, an energy company that serves 16 million Californians across a 70,000-square-mile service area in Northern and Central California. For more information, visit http://www.pgecorp.com.

SOURCE PG&E Corporation

Share this article

BOGOTÁ, Colombia, Sept. 24, 2026 /PRNewswire/ -- Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) (the "Company") announces that, at a meeting held today, its Board of Directors, acting unanimously and with the full participation of all its members, appointed Mr. Joaquín Gutiérrez Caballero as Chief Executive Officer and principal legal representative of the Company. Mr. Gutiérrez Caballero will assume the position on a permanent basis, effective September 28, 2026. Accordingly, the interim appointment of Mr. Camilo Barco as Chief Executive Officer will conclude effective September 27, 2026.

The appointment was made following a selection process conducted by the Board's Compensation, Nomination and Culture Committee, in accordance with the Company's Succession Policy, and upon the Committee's recommendation to select a leader with strong stakeholder engagement and coordination capabilities to lead the Company through its next phase of development amid a particularly challenging environment.

Mr. Gutiérrez Caballero holds a degree in Business Administration, together with postgraduate specializations in Telecommunications Project Management, Telecommunications Law, and Healthcare Services Management. He has more than 30 years of professional experience.

The priorities identified for the incoming Chief Executive Officer include advancing the Company's renewal through initiatives designed to strengthen value creation, promote rigorous and transparent management practices, and enhance engagement and collaboration with the Colombian State, local communities, investors, employees, and other stakeholders.

These objectives are expected to be pursued with the support of a highly qualified technical team committed to strengthening the Company's position in the markets in which it operates and to delivering long-term value for its stakeholders.

The Board of Directors of Ecopetrol S.A. has expressed its full support for Mr. Joaquín Gutiérrez Caballero as he assumes this leadership role and undertakes the responsibilities associated with the Company's transformation, renewal, and continued consolidation as a leading enterprise in Colombia.

Ecopetrol is the largest company in Colombia and one of the main integrated energy companies in the American continent, with more than 19,000 employees. In Colombia, it is responsible for more than 60% of the hydrocarbon production of most transportation, logistics, and hydrocarbon refining systems, and it holds leading positions in the petrochemicals and gas distribution segments. With the acquisition of 51.4% of ISA's shares, the company participates in energy transmission, the management of real-time systems (XM), and the Barranquilla–Cartagena coastal highway concession. At the international level, Ecopetrol has a stake in strategic basins in the American continent, with drilling and exploration operations in the United States (Permian basin and the Gulf of Mexico), Brazil, and Mexico, and, through ISA and its subsidiaries, Ecopetrol holds leading positions in the power transmission business in Brazil, Chile, Peru, and Bolivia, road concessions in Chile, and the telecommunications sector.

This release contains statements that may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All forward-looking statements, whether made in this release or in future filings or press releases, or orally, address matters that involve risks and uncertainties, including in respect of the Company's prospects for growth and its ongoing access to capital to fund the Company's business plan, among others. Consequently, changes in the following factors, among others, could cause actual results to differ materially from those included in the forward-looking statements: market prices of oil & gas, our exploration, and production activities, market conditions, applicable regulations, the exchange rate, the Company's competitiveness and the performance of Colombia's economy and industry, to mention a few. We do not intend and do not assume any obligation to update these forward-looking statements.

For more information, please contact:

Investor Relations Office

Email: [email protected] 

Corporate Communications (Colombia)

Email: _[email protected]  

SOURCE Ecopetrol S.A.

Share this article

EASTON, Pa., Sept. 24, 2026 /PRNewswire/ -- What steps keep market-rate residential construction on schedule and on budget? A new HelloNation article explains how effective construction management reduces uncertainty and safeguards return on investment during every stage of residential development.

The article outlines a structured approach to planning, coordination, and oversight, emphasizing how construction management creates predictability in complex projects. The focus begins with pre-construction planning, where key factors like cost modeling, material availability, and labor assumptions are assessed early. By analyzing drawings for constructability and identifying potential design challenges, the process helps reduce change orders and schedule disruptions later in the build.

The article makes clear that pre-construction planning serves as the foundation for success in market-rate residential projects. With accurate cost modeling, owners can make informed decisions before construction begins. The article points out that this early clarity is critical to maintaining alignment with financial targets throughout the project.

Construction Management Expert Jovana Villanueva of Easton, PA, explains that trade coordination and communication are essential once building begins. The article details how day-to-day trade coordination ensures that subcontractors work efficiently and in the correct sequence. This reduces on-site congestion and quality issues, helping the entire team stay on track.

The article also highlights how ongoing quality control is built into the entire workflow. Rather than treating inspections as a final step, construction managers monitor materials and installation methods throughout the project. This approach reduces costly rework and protects the property's long-term value—both of which support the project's return on investment.

Another major focus in the article is schedule management. It notes that many market-rate residential projects run into trouble when timelines are based on optimistic assumptions rather than field data. The article emphasizes the role of construction managers in tracking actual progress and making real-time adjustments to keep owners fully informed. This transparency is key to managing financing, leasing, and occupancy plans.

At every step, from pre-planning to turnover, construction management aligns design goals with financial performance. The article explains how managers work with architects and engineers to select materials and systems that offer long-term durability rather than just low initial cost. Long-lead items are flagged early to avoid pricing spikes and delivery delays, which can threaten project outcomes.

For developers involved in residential development, the article argues that construction management is not just oversight—it's a disciplined system that ties every decision back to performance, cost, and timeline. By maintaining tight trade coordination, detailed scheduling, and clear communication, construction managers reduce risk and improve outcomes.

The importance of ongoing reporting is also addressed. The article describes how regular updates on costs, schedules, and risks help investors and stakeholders stay confident in the project's financial outlook. This level of control and insight helps ensure that each market-rate residential project delivers on its intended return on investment.

The Construction Management Workflow Behind Market-Rate Residential Developments features insights from Jovana Villanueva, Construction Expert of Easton, PA, in HelloNation.

About HelloNation

HelloNation is a premier media platform that connects readers with trusted professionals and businesses across various industries. Through its innovative "edvertising" approach that blends educational content and storytelling, HelloNation delivers expert-driven articles that inform, inspire, and empower. Covering topics from home improvement and health to business strategy and lifestyle, HelloNation highlights leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 22, 2026, Dr. Reddy's announced its first quarter fiscal 2027 earnings, reporting, among other things, earnings per share of only $0.06, due in part to the adverse impact of a ₹2.4 billion provision related to out-of-specification semaglutide batches. CEO Erez Israeli said that "[t]he quarter's EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives and other associated costs."

On this news, Dr. Reddy's stock price fell $1.18 per share, or 9.4%, to close at $11.38 per share on July 22, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Danielle Peyton

Pomerantz LLP

[email protected]

646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Share this article

ARK Invest Launches Its First Income Strategy, ARKY, Targeting 17.5% Income Through Its Innovation Equity Universe

Where Innovation Meets Income, ARK Presents a Compelling New Opportunity For Investors

ST. PETERSBURG, Fla., Aug. 19, 2026 /PRNewswire/ -- ARK Investment Management LLC ("ARK" or "ARK Invest"), an investment adviser focused solely on disruptive innovation, today announced the launch of the ARK Active Autocallable Income ETF (ARKY). ARKY is now trading on the Cboe BZX Exchange.

The ARK Active Autocallable Income ETF is designed to combine ARK's innovation-driven equity universe with a systematic volatility harvesting strategy seeking to deliver a high-yield income premium or payment stream based on the market price movements of the referenced equities in a single ETF structure. The strategy provides investors with:

- A target 17.5% coupon. ARKY targets one of the most compelling income profiles in the autocallable ETF category. The portfolio is actively managed to prioritize consistency of income delivery over headline yield, seeking to ensure that target coupon is realized in investors' accounts.*

- Actively managed. ARKY's sub-advisor, SCG Asset Management, calibrates strike levels, maturities, and payoff structures on a position-by-position basis as market conditions evolve, with the goal of minimizing net asset value (NAV) erosion and maintaining stable income generation over time.

- Built on ARK's innovation companies. Each position in the portfolio references a single stock from ARK's high-conviction innovation universe. Innovation stocks carry higher realized volatility than the broad market, and ARKY is structured to harvest that volatility and convert it into a consistent yield stream.

- Diversified across 25–50 single-stock autocallables. Each holding in ARKY features a 50 to 60% coupon barrier, isolating risk at the position level. A breach in any single underlying asset affects only that position while the remainder of the portfolio could continue generating income.

- The income profile of a structured note, in the simplicity of an ETF. ARKY delivers the autocallable payoff profile historically available only through bank-issued structured notes, in a daily-liquid ETF with 1099 tax reporting, no investment minimums, and no lock-up periods.

"As investor interest in autocallable ETFs continues to grow, we believe active management is critical," said Rahul Bhushan, ARK's Global Head of Investment Products. "ARKY is designed to provide risk-managed exposure to autocallable strategies within a transparent and liquid ETF structure. By using ARK's innovation-focused equity universe as underlying reference assets, the fund seeks to transform the return profile of those stocks into an income-oriented solution targeting a 20% annual income rate."

"Innovation has historically been viewed as a source of growth, not income. ARKY challenges that assumption," stated Cathie Wood, ARK's Founder, CIO. "We believe the volatility created by disruptive innovation is not simply a risk to be managed but an opportunity to be harvested. ARKY is designed to convert that volatility into a compelling income stream, opening innovation investing to an entirely new audience."

Why Now?

Fixed income has long been a staple in investor portfolios. Dividend strategies have attracted a wide range of investors for decades. Now, equity income products have grown into a $180 billion-plus market. ARKY sits at the intersection of two things that appeal to very different audiences: ARK's innovation equity universe and an income-generating autocallable structure, reaffirming ARK's mission to make disruptive innovation accessible to all. As investors seek new sources of income beyond traditional fixed income and dividend strategies, ARK believes elevated volatility across innovative growth companies creates a unique opportunity to generate attractive cash flow. ARKY was designed to capitalize on this market dynamic through an actively managed autocallable portfolio. For advisor inquiries, please contact your American Beacon sales representative. Retail investors can reach ARK directly at [email protected].

About ARK Invest

ARK Investment Management LLC is a federally registered investment adviser and privately held firm headquartered in St. Petersburg, Florida. Founded by Cathie Wood in 2014, ARK focuses solely on disruptive innovation, aiming to identify large-scale investment opportunities across artificial intelligence, robotics, energy storage, multiomic sequencing, blockchain technology, and beyond.

For more information about the ARK Active Autocallable Income ETF, visit www.ark-funds.com/funds/arky.

*ARKY seeks the target yield and current income exposure through Synthetic Equity-Linked Notes (Synthetic ELNs). A Synthetic ELN is a structured instrument, built using options or other derivatives rather than a traditional issued note, that is designed to replicate the economic exposure of an equity-linked note. In ARKY's case, this exposure is tied to the performance of ARK's innovation equity universe.

Important Information

Investors should carefully consider the investment objectives and risks as well as charges and expenses of an ARK ETF before investing. This and other information are contained in the ARK ETFs' prospectuses and summary prospectuses, which may be obtained by visiting www.ark-funds.com. The prospectus and summary prospectus should be read carefully before investing.

An investment in an ARK ETF is subject to risks and you can lose money on your investment in an ARK ETF. There can be no assurance that the ARK ETFs will achieve their investment objectives. The ARK ETFs' portfolios are more volatile than broad market averages. The ARK ETFs also have specific risks, which are described in the ARK ETFs' prospectuses.

The principal risks of investing in the ARK Active Autocallable Income ETF (ARKY) include: Derivatives Risk: The Fund's use of derivatives involves risks that may be greater than those associated with traditional investments, including market, leverage, liquidity, counterparty, and valuation risks. Changes in the value of an underlying asset may result in losses that exceed the Fund's initial investment. Derivatives may be difficult to value or exit, particularly during periods of market stress, and the Fund could experience losses if a counterparty fails to meet its obligations. Leverage Risk: The Fund's use of leverage may magnify gains and losses, increase volatility, and cause the Fund to liquidate investments at unfavorable times to meet its obligations. Liquidity Risk — Synthetic ELNs: There is no liquid secondary trading market for Synthetic ELNs. Terminating the Synthetic ELNs may require the payment of a premium or acceptance of a discounted price and may take longer to complete. These features may adversely impact the value of the Synthetic ELNs and the value of your investment. Equity Securities Risk – Synthetic ELNs: The Fund gains its investment exposure primarily through Synthetic ELNs that reference individual equity securities. The value of these Synthetic ELNs may decline due to market conditions, economic events, industry developments, company-specific factors, changes in interest rates, inflation, or investor sentiment affecting the underlying reference securities. Broad market declines may adversely affect the value of the Fund's investments and performance. SPAC Risk: The Fund's Synthetic ELNs may reference Special Purpose Acquisition Companies (SPACs). SPAC investments may be speculative and highly dependent on management's ability to complete and successfully execute a business combination. If a transaction is not completed or does not perform as expected, the value of the referenced SPAC securities, and therefore the Fund's Synthetic ELNs, may decline. Disruptive Innovation Risk: The Fund's Synthetic ELNs may reference companies pursuing disruptive technologies or business models. Such companies may fail to develop, commercialize, or profit from innovative technologies, may face significant competition or regulatory challenges, and may experience greater volatility than the broader market. The success of a disruptive innovation may not translate into improved financial performance or higher security values, which could adversely affect the Fund's performance. Additional risks of investing in ARKY include market, management and non-diversification risks as well as risks associated with the various sectors and industries in which the fund invests. Detailed information regarding the specific risks of the ARKY ETF can be found in the prospectus.

New Fund Risk. There can be no assurance that the Fund will grow to or maintain an economically viable size, in which case the Board may determine to liquidate the Fund if it determines that liquidation is in the best interest of shareholders. Liquidation of the Fund can be initiated without shareholder approval. As a result, the timing of the Fund's liquidation may not be favorable.

Shares of ARK ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. ETF shares may only be redeemed directly with the ETF at NAV by Authorized Participants, in very large creation units. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.

ARK Investment Management, LLC is the investment adviser to the ARK ETFs.

Foreside Fund Services LLC, distributor.

Shaina Lamb

517.652.1296

[email protected]

SOURCE ARK Investment Management LLC

Share this article

Thrive Care Services LLC allegedly failed to accurately record employees' full time worked, including time worked off the clock. This, allegedly, resulted in violations to various California Labor Laws.

**THIS IS AN ATTORNEY ADVERTISEMENT**

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- The San Diego employment law attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, filed a class action complaint alleging that Thrive Care Services LLC, violated the California Labor Code. The Thrive Care Services LLC, class action lawsuit, Case No. 26CU043450C, is currently pending in the San Diego County Superior Court of the State of California. A copy of the Complaint can be read here.

According to the lawsuit filed against Thrive Care Services LLC, the company allegedly failed to provide Plaintiff with all legally required meal and rest periods. From time to time, Plaintiff was allegedly asked to work in excess of four (4) hours without being provided ten (10) minutes rest periods. Further these employees were denied their first rest periods of at least ten (10) minutes for some shifts of at least two (2) to four (4) hours from time to time, a first and second rest period of at least ten (10) minutes for some shifts worked of between six (6) and eight (8) hours from time to time, and a first , second and third rest period of at least ten (10) minutes for some shifts worked of ten (10) hours or more from time to time.

The lawsuit further alleges that Defendant underpaid sick wages to Plaintiff by failing to pay such wages at the regular rate of pay, when sick pay was paid, it was paid at the base rate of pay. Defendant failed to reimburse and indemnify Plaintiff for required business expenses associated with their job duties. Defendant allegedly violated Cal. Lab. Code §§ 246(1)(2) and 2802.

For more information about the class action lawsuit against Thrive Care Services LLC, call (800) 568-8020 to speak to an experienced California employment attorney today.

Blumenthal Nordrehaug Bhowmik De Blouw LLP is an employment law firm with offices located in San Diego, San Francisco, Sacramento, Los Angeles, Riverside and Chicago that dedicates its practice to helping employees, investors and consumers fight back against unfair business practices, including violations of the California Labor Code and Fair Labor Standards Act. If you need help in collecting unpaid overtime wages, unpaid commissions, being wrongfully terminated from work, and other employment law claims, contact one of their attorneys today.

**THIS IS AN ATTORNEY ADVERTISEMENT**

Media Contact

Nicholas De Blouw

Blumenthal Nordrehaug Bhowmik De Blouw LLP

(800) 568-8020

[email protected]

https://www.bamlawca.com/ 

SOURCE Blumenthal Nordrehaug Bhowmik De Blouw LLP

Share this article

Live webcams and certified staff make Camp Bow Wow's overnight boarding a transparent alternative to traditional kennels

WESTMINSTER, Colo., Sept. 24, 2026 /PRNewswire/ -- For many pet parents, the hardest part of traveling is not the flights or itinerary, but trusting someone else with their dog's care overnight. Camp Bow Wow, the nation's leading dog boarding and daycare franchise, addresses that concern with an overnight dog boarding experience built on real-time visibility, transparency and play.

With locations nationwide offering 24-hour dog boarding, Camp Bow Wow's overnight dog boarding experience is designed around visibility and peace of mind, allowing pet parents to view a live webcam feed from a phone, laptop or tablet to watch their dog play and socialize.

"Your pup's experience with dog boarding affects everyone in the family, the dog and the pet parent alike," said Camp Bow Wow VP of Marketing Kate Wright. "Our webcams exist because we believe transparency builds trust. When a pet parent can see their dog running around the play yard and making new friends, that worry turns into confidence."

How Local Dog Boarding Looks Different at Camp Bow Wow

Traditional kennels often mean long stretches of confinement with little insight for pet parents. However, Camp Bow Wow's overnight dog boarding model was built around openness, active play and supervision from Certified Camp Counselors.

Every overnight stay includes:

- Live webcam access in play yards, giving pet parents a direct view of their dog's day

- Open-play dog boarding all day, with socialization in large, climate-controlled play yards

- Cozy, private Cabins with comfy cots and fleece blankets for overnight rest

- Dog daycare included with every overnight boarding stay, so dogs receive physical exercise and mental stimulation

- Pet First Aid and CPR Certified Camp Counselors on-site monitoring dogs during play

- Option to add personalized enrichments tailored to each dog's comfort level

The Role of Webcams in Building Trust

Camp Bow Wow's live webcam system is central to what makes its overnight dog boarding experience different from a traditional kennel stay. Rather than asking pet parents to simply trust that their dog is safe, Camp Bow Wow shows them.

- Pet parents can check in on their dog's play yard activity at any time of day

- Webcam access reinforces Camp Bow Wow's broader commitment to transparency in how dogs are cared for while boarding

What a Typical Overnight Stay Looks Like

Every overnight dog boarding stay at Camp Bow Wow follows a full day of open play, supervised by Certified Camp Counselors, and a comfortable night's rest in a Cabin. Pet parents can watch the entire day unfold in real time through the webcam feed during open play hours.

A typical stay at Camp Bow Wow looks like:

- Dogs arriving and settling into daycare while socializing with other Campers in supervised play yards

- Certified Camp Counselors monitoring play, behavior and energy levels throughout the day

- As evening approaches, dogs wind down and move to their private Cabins for overnight rest

- Pet parents can check the webcam feed throughout the day to see their dog in action

Frequently Asked Questions

Are Camp Bow Wow webcams live?

Yes. Camp Bow Wow's webcams stream live video from its play yards during open play hours, giving pet parents a real-time view of their dog's day rather than a recorded or delayed feed.

Can I watch my dog during boarding?

Yes. Pet parents can watch their dog during boarding through Camp Bow Wow's live webcam access, available from a phone, laptop or tablet at any time during open play hours, whether their dog is visiting for a single overnight stay or an extended boarding period.

How do dog daycare webcams work?

Camp Bow Wow's dog daycare webcams are positioned in play yards and stream live video that pet parents can access remotely. Rather than asking pet parents to simply trust that their dog is safe and happy, the webcams let them see their dog playing and socializing throughout the day, reinforcing the brand's broader commitment to transparency in care.

Do dog daycares have webcams?

Webcam availability varies by daycare provider. However, all Camp Bow Wow locations include live webcam access in play yards as a standard part of both its daycare and overnight boarding experience, a feature that sets it apart from other providers or traditional kennels.

How do Camp Bow Wow's webcams help with boarding anxiety?

The webcams give pet parents real-time visibility into their dog's day, which helps ease the uncertainty that often comes with boarding for the first time or for an extended stay. Seeing a dog playing and socializing builds confidence in the care being provided.

What makes Camp Bow Wow's overnight boarding different from a traditional kennel?

Rather than confining dogs to individual kennels for long stretches, Camp Bow Wow offers open, supervised group play throughout the day, followed by rest in a private Cabin overnight. Dog daycare is included with every overnight stay.

Can I check on my dog during an extended or long-term boarding stay?

Yes. Webcam access is available throughout a dog's stay, whether it is a single overnight or an extended boarding period.

About Camp Bow Wow

Camp Bow Wow® is a leading dog daycare and boarding provider in the rapidly growing pet care industry, with over 225 units in 42 states and Canada. For more than 25 years, Camp Bow Wow has brought joy to dogs and pet parents with the highest level of safety, service and fun. In addition to daycare and overnight boarding, the company offers personalized enrichment opportunities, including the proprietary Pawsitive Start Jr. Program for puppy education and socialization, grooming services and a rewards-based dog training program. The Camp Bow Wow brand also includes the Bow Wow Buddies Foundation®, a 501(c)(3) nonprofit organization dedicated to providing urgent medical care funds to rescue groups and pet parents who cannot afford their veterinary bills. Camp Bow Wow is part of the Propelled Brands® family of brands, a recognized leader in the franchising industry, and has been ranked on ENTREPRENEUR's Franchise 500 list for the past 17 years. To learn more about Camp Bow Wow, visit campbowwow.com.

SOURCE Camp Bow Wow

Share this article

Tea and Trumpets | Sunday, October 11 | 3 PM

The Fall Series opens with Tea and Trumpets, VMF's signature intimate experience pairing an elegant afternoon tea service with live brass quintet performance. A local favorite, the event returns by popular demand for another season, hosted at the historic Pierpont Inn.

Birth of Impressionism | Thursday, October 15 | The Museum of Ventura County | 7 PM

VMF's popular Classical Edge Concert format returns with Birth of Impressionism, an evening that is part performance, part history, and part discovery. Led by VMF Artistic Director and violinist Nuvi Mehta, the event takes audiences inside a pivotal moment in musical history, bringing the ideas and sounds of the Impressionist movement to life through storytelling and live music.

TAKE3: Where Rock Meets Bach | Friday, October 16 | Ventura Music Hall | 7 PM

On Friday, October 16, TAKE3 takes the stage at Ventura Music Hall for a genre-smashing evening that pairs the technical precision of Bach with the energy and irreverence of rock. The violin, cello, and piano trio -- conservatory-trained and rock-star electrifying -- has built a devoted following for performances as surprising as they are virtuosic. This event is ticketed directly through Ventura Music Hall.

Michael Cleveland and Jason Carter | Saturday, October 17 | Mission Park, Ventura | 5 PM

On Saturday, October 17, VMF brings the two most decorated fiddle players in the history of the International Bluegrass Music Association to Mission Park in Ventura. Michael Cleveland, a 12-time IBMA Fiddle Player of the Year, joins 6-time winner Jason Carter for an outdoor performance that celebrates the finest traditions of American roots music in one of Ventura's most beloved community settings. Sponsored by Vita Arts Center, The Welcome Room, Ofi Property and Daly Group

Pacific Jazz Orchestra: A Tribute to Quincy Jones | Sunday, October 18 | Rancho Campana Performing Arts Center, Camarillo | 3 PM

The Fall Series centerpiece brings Pacific Jazz Orchestra to Rancho Campana Performing Arts Center for an exploration of Quincy Jones' masterful early work from the 1950s and 60s. Seven-time Grammy-nominated Artistic Director and conductor Chris Walden -- who counts Jones himself among his mentors -- leads the group's 19-piece Big Band Ensemble through original arrangements drawn from Jones' groundbreaking recordings, his arrangements for legendary singers including Frank Sinatra and Sarah Vaughan, and his film scoring work on landmarks such as The Pawnbroker (1964) and In the Heat of the Night (1967).

Guest vocalists Nayanna Holley and Adam "Aejaye" Jackson join for the occasion. Holley, a longtime member of the house band for NBC's The Voice, brings extraordinary range as a performer and vocal contractor whose credits span The Color Purple, Encanto, and The Academy Awards. Jackson, a Detroit-born vocalist, songwriter, and actor, brings a soulful blend of R&B, soul, and jazz shaped by decades of collaboration with artists including Stevie Wonder, Josh Groban, Toni Braxton, and David Foster.

Pacific Jazz Orchestra has garnered critical acclaim for performances that "entertain, inspire, and enrich" (Variety). The 40-piece Los Angeles-based ensemble is recognized as the city's first resident jazz orchestra since 2006. Tickets for the October 18 concert are $15 -- $109, available at venturamusicfestival.org or by calling (805) 648-3146. The concert takes place at Rancho Campana Performing Arts Center, 4235 Mar Vista Drive, Camarillo, CA 93010.

Chanticleer | Tuesday, December 15 | Ventura Center for Spiritual Living | 7 PM

VMF's 31st season closes December 15 with a special holiday concert from Chanticleer, the celebrated twelve-voice male ensemble that has sold over one million recordings and performed thousands of concerts across the globe. Named for the clear-singing rooster in Geoffrey Chaucer's Canterbury Tales, the ensemble spans countertenor to bass and performs five centuries of choral music with breathtaking precision. The performance at Ventura Center for Spiritual Living brings the season to a warm and luminous close.

Tickets

Tickets for all VMF-presented Fall Series events are on sale now at venturamusicfestival.org or by calling (805) 648-3146. VMF also offers subsidized ticket pricing and free programming to ensure music remains accessible throughout the community.

About the Ventura Music Festival

A 501(c)(3) nonprofit organization since 1995, the Ventura Music Festival has been a cornerstone of cultural life in Ventura for over thirty years, presenting world-class performances while championing music education and free community programming. VMF's Music in the Schools program serves more than 1,600 students annually, and the organization delivers free community concerts each season, reaching a total community audience of 10,100+. The 2026 season is presented with generous support from Impresario Season Sponsors, the John and Glenda Hammer Family. For tickets and information, visit venturamusicfestival.org or call (805) 648-3146.

SOURCE Ventura Music Festival

Share this article

PUNE, India, Sept. 24, 2026 /PRNewswire/ -- The Global Multiple Sclerosis Treatment Market was valued at USD 26.76 Billion in 2025 and is projected to expand at a 5.8% CAGR from 2026 to 2034, reaching USD 44.45 Billion by 2034, according to a new analysis by Maximize Market Research.

Global Multiple Sclerosis Treatment Market

The Global Multiple Sclerosis Treatment Market Report 2025 provides a comprehensive analysis of market trends, multiple sclerosis prevalence, patient population, disease burden, treatment adoption, disease-modifying therapies, clinical research, treatment pipeline, therapeutic innovations, regulatory developments, competitive landscape, and market forecasts through 2034. The market covers clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), and secondary progressive multiple sclerosis (SPMS) across medications, stem cell therapy, physical therapy, plasma exchange, and other treatment approaches.

The rising prevalence of multiple sclerosis, increasing awareness of early diagnosis, growing demand for disease-modifying therapies, and expanding access to advanced neurological care are supporting the growth of the global Multiple Sclerosis Treatment Market. Increasing adoption of immunomodulators, immunosuppressants, interferons, oral disease-modifying therapies, monoclonal antibodies, and high-efficacy treatments is transforming multiple sclerosis management. Growing investments in neurological research, clinical trials, pharmaceutical R&D, and next-generation treatment development are further expanding therapeutic opportunities for patients with relapsing and progressive forms of multiple sclerosis.

Advancements in monoclonal antibody therapies, B-cell-targeted treatments, oral disease-modifying therapies, precision medicine, biomarker-based treatment strategies, neuroprotective approaches, remyelination therapies, stem cell research, and digital health solutions are reshaping the multiple sclerosis treatment landscape. Increasing research into relapsing-remitting MS, primary progressive MS, secondary progressive MS, and early-stage disease management is creating new opportunities for pharmaceutical and biotechnology companies. Regulatory approvals, clinical trial advancements, strategic collaborations, licensing agreements, pipeline expansion, and investments in next-generation neurological therapies are expected to accelerate innovation and strengthen the global Multiple Sclerosis Treatment Market through 2034.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/54201/

Global Multiple Sclerosis Treatment Market gains momentum as rising disease prevalence, growing demand for disease-modifying therapies, increasing adoption of high-efficacy biologics and oral treatments, advances in monoclonal antibody therapies and precision medicine, and expanding research into next-generation neurological treatments accelerate therapeutic innovation: Maximize Market Research unveils key market insights.

Global Multiple Sclerosis Treatment Market Size & Forecast

Global Multiple Sclerosis Treatment Market Trends & Insights

- North America leads the Global Multiple Sclerosis Treatment Market, supported by high MS prevalence, advanced healthcare infrastructure, strong neurological research, established pharmaceutical companies, and widespread adoption of disease-modifying therapies.

- Asia-Pacific is a high-growth region, driven by improving healthcare infrastructure, increasing awareness of neurological disorders, rising healthcare expenditure, better diagnostic capabilities, and expanding access to advanced MS treatments.

- Disease-modifying therapies and high-efficacy biologics are gaining adoption, with growing use of monoclonal antibodies, immunomodulators, immunosuppressants, and other advanced therapies to manage relapses and slow disease progression.

- Oral therapies and personalized treatment approaches are expanding, supported by increasing patient preference for convenient treatment options, advances in biomarker-based treatment selection, precision medicine, and digital health solutions for disease monitoring.

- Next-generation MS therapies are driving treatment innovation, with increasing research into BTK inhibitors, neuroprotective therapies, remyelination therapies, stem cell approaches, and treatments targeting progressive forms of multiple sclerosis.

Rising Multiple Sclerosis Prevalence and Demand for Disease-Modifying Therapies Drive Market Growth

The increasing prevalence of multiple sclerosis, growing awareness of neurological disorders, improved diagnostic capabilities, and rising emphasis on early disease management are driving demand for effective MS treatments. Growing adoption of disease-modifying therapies (DMTs), including immunomodulators, immunosuppressants, interferons, oral therapies, monoclonal antibodies, and high-efficacy biologics, is supporting market expansion across relapsing and progressive forms of multiple sclerosis.

High Treatment Costs and Limited Access to Advanced Therapies Restrain Market Growth

The high cost of long-term multiple sclerosis treatment, advanced biologic drugs, disease-modifying therapies, continuous monitoring, and specialized neurological care can limit patient access. Expensive monoclonal antibody therapies and innovative treatments, combined with limited reimbursement coverage and affordability concerns in emerging economies, can restrict the adoption of advanced MS therapies.

Next-Generation Therapies and Precision Medicine Create Market Opportunities

Advances in next-generation multiple sclerosis therapies are creating significant opportunities for pharmaceutical and biotechnology companies. Growing research into BTK inhibitors, neuroprotective therapies, remyelination therapies, stem cell therapy, personalized medicine, biomarker-based treatment strategies, and novel immunotherapies is expanding the MS treatment pipeline. Increasing clinical research, digital health solutions, remote patient monitoring, and innovative approaches for progressive multiple sclerosis are further creating opportunities across the global market.

Limited Specialized Neurological Care and Treatment Accessibility Create Challenges

Limited access to specialized neurological care, advanced diagnostic facilities, trained healthcare professionals, and innovative disease-modifying therapies remains a challenge in several emerging markets. Differences in healthcare infrastructure, reimbursement coverage, treatment affordability, regulatory requirements, and availability of advanced MS therapies can restrict the adoption of innovative multiple sclerosis treatments. Additionally, the need for long-term treatment and continuous patient monitoring can create challenges for healthcare systems and patients.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/54201/

Global Multiple Sclerosis Treatment Market Segmentation

The Global Multiple Sclerosis Treatment Market is segmented by Type, Treatment, Drug Class, Diagnosis, Route of Administration, End User, and Region. Rising multiple sclerosis prevalence, increasing demand for disease-modifying therapies, growing adoption of advanced immunotherapies, improvements in neurological diagnosis, and expanding research into next-generation MS treatments are supporting market development across these segments.

North America Leads the Multiple Sclerosis Treatment Market While Asia Pacific Emerges as a High-Growth Region

North America held the largest share of the Global Multiple Sclerosis Treatment Market in 2025, supported by high multiple sclerosis prevalence, advanced healthcare infrastructure, strong neurological research, and high healthcare expenditure. The United States represents a major market due to the presence of leading pharmaceutical companies, advanced neurology centers, extensive clinical research, and high adoption of disease-modifying therapies (DMTs), monoclonal antibodies, oral therapies, and high-efficacy biologics. Canada and Mexico are also contributing through improving healthcare infrastructure, increasing neurological disease awareness, and expanding access to advanced multiple sclerosis treatments.

Europe represents an important market, supported by established healthcare systems, strong pharmaceutical and biotechnology industries, and increasing investments in neurological research. Germany, the United Kingdom, France, Italy, Spain, Sweden, Austria, and other European countries are witnessing growing adoption of disease-modifying therapies, immunomodulators, immunosuppressants, oral DMTs, monoclonal antibody therapies, and personalized treatment approaches. Favorable reimbursement frameworks, clinical research activities, and regulatory support for innovative neurological treatments are further supporting regional market development.

Asia Pacific is expected to witness strong growth as healthcare infrastructure, neurological disease awareness, diagnostic capabilities, and access to advanced multiple sclerosis therapies improve. China, Japan, India, South Korea, Australia, and other regional markets are contributing to market development. Rising healthcare expenditure, pharmaceutical investments, clinical trials, neurological research, and increasing availability of disease-modifying therapies are creating new opportunities for advanced MS treatment adoption. Growing awareness of early diagnosis and specialized neurology services is further supporting regional expansion.

Middle East & Africa is gradually developing as healthcare infrastructure and access to specialized neurological care improve.

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether EyePoint and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On August 17, 2026, EyePoint issued a press release "announc[ing] topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD)." The press release disclosed that change from baseline in best corrected visual acuity versus 2 mg aflibercept (Regeneron Pharmaceuticals' (REGN) Eylea) was not met in the entire dataset.

On this news, EyePoint's stock price fell $9.88 per share, or 66.98%, to close at $4.87 per share on August 17, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Danielle Peyton

Pomerantz LLP

[email protected]

646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Share this article